Yu Ting, Yan ShiFan, Chi ZhenHai, Cheng Pan, Li HaiYan, Qin SiYu, Li MingHui, Chen RiXin, Jiao Lin
Jiangxi University of Traditional Chinese Medicine.
Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
Medicine (Baltimore). 2020 Oct 23;99(43):e22521. doi: 10.1097/MD.0000000000022521.
Traditional Chinese medicine has been widely used in the treatment of allergic rhinitis. However, currently randomized controlled trials (RCTs) and meta-analysis only compare 1 or 2 types of traditional Chinese medicine therapies, and the comprehensive ranking of efficacy and safety of multiple traditional Chinese medicine therapies for the treatment of allergic rhinitis has not been completed. Therefore, the purpose of this network meta-analysis is to evaluate the efficacy and safety of different traditional Chinese medicine therapies for the treatment of allergic rhinitis.
Three English databases of PubMed, Embase, Cochrane Library, and 2 Chinese databases of CNKI and Wanfang were searched from their inceptions to September 1, 2020. At the same time, in order to prevent omissions, we also compared the previous meta-analysis to determine the final included trials. The main evaluation outcome was the total Clinical Score (total nasal symptom score [TNSS]), the secondary evaluation outcome was the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and adverse events. The Cochrane Collaboration's Tool was used to evaluate the methodological quality of articles, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) instrument was used to evaluate the quality of evidence. Network meta-analysis was completed by using Stata Statistical Software (Version 14.0, Stata Corporation, College Station, TX).
This study will compare and rank the different traditional Chinese medicine therapies for allergic rhinitis.
This study is the first time to use network meta-analysis (NMA) to compare the efficacy and safety of traditional Chinese medicine for the treatment of allergic rhinitis, which will provide ideas and methods for the clinical treatment for allergic rhinitis.
No. INPLASY202080119.
中药已广泛应用于过敏性鼻炎的治疗。然而,目前的随机对照试验(RCT)和荟萃分析仅比较1或2种中药疗法,多种中药疗法治疗过敏性鼻炎的疗效和安全性综合排名尚未完成。因此,本网状荟萃分析的目的是评估不同中药疗法治疗过敏性鼻炎的疗效和安全性。
检索了三个英文数据库PubMed、Embase、Cochrane图书馆以及两个中文数据库CNKI和万方,检索时间从建库至2020年9月1日。同时,为防止遗漏,我们还比较了之前的荟萃分析以确定最终纳入的试验。主要评估结局为总临床评分(总鼻症状评分[TNSS]),次要评估结局为变应性鼻炎生活质量问卷(RQLQ)和不良事件。采用Cochrane协作网工具评估文章的方法学质量,采用推荐分级的评估、制定与评价(GRADE)工具评估证据质量。使用Stata统计软件(版本14.0,Stata公司,美国德克萨斯州大学城)完成网状荟萃分析。
本研究将比较并排列治疗过敏性鼻炎的不同中药疗法。
本研究首次采用网状荟萃分析(NMA)比较中药治疗过敏性鼻炎的疗效和安全性,将为过敏性鼻炎的临床治疗提供思路和方法。
INPLASY注册号:INPLASY202080119。